HWM
JAZZ icon

HighMark Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

HighMark Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40
Closed -$7K – 516
2021
Q1 		$7K Sell
40
-19
-32% -$3.13K 0.01% 298
2020
Q4 		$10K Sell
59
-298
-83% -$44.4K 0.01% 231
2020
Q3 		$51K Buy
+357
New +$44.3K 0.05% 105

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighMark Wealth Management's JAZZ Position: Q2 2021 in Review

HighMark Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2021, closing a stake of 40 shares — an estimated $7K sold.

HighMark Wealth Management first reported a position in JAZZ in Q3 2020 and held it in 3 quarters. The position peaked at $51K in Q3 2020. 505 funds tracked by Wall St. Rank hold JAZZ as of Q2 2021.

  • HighMark Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • HighMark Wealth Management sold 40 Jazz Pharmaceuticals shares in Q2 2021, an estimated $7K.
  • HighMark Wealth Management first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • HighMark Wealth Management's Jazz Pharmaceuticals position peaked at $51K in Q3 2020.
  • 505 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2021.

Based on HighMark Wealth Management's 13F filing for Q2 2021, filed 2 Aug 2021.